Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 M.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 M.
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 3.5% M
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% in Dextrose 25% is a combination of amino acids and dextrose for parenteral nutrition. Amino acids provide nitrogen and essential substrates for protein synthesis, while dextrose provides a caloric source to prevent protein catabolism. The mechanism involves infusion into the bloodstream, bypassing gastrointestinal digestion, to maintain or restore nitrogen balance and provide energy.
Provides essential and nonessential amino acids for protein synthesis, serving as substrates for anabolic processes in parenteral nutrition.
Intravenous infusion. Amino acid dose based on protein requirements: 0.8-1.0 g/kg/day for stable patients, up to 1.5-2.0 g/kg/day for catabolic states. Dextrose dose based on caloric needs: typically 150-300 g/day. Infuse via central line at rates not exceeding 0.5 g/kg/hour dextrose. Typical starting rate: 50-100 mL/hr, titrated based on metabolic tolerance.
Intravenous infusion of 1.2 to 2.2 g amino acids per kg per day, adjusted to meet metabolic and nutritional requirements. Typical adult dose: initial infusion rate of 50 mL/hour, increasing to 125 mL/hour (4.4 g amino acids per hour) based on tolerance. Not for direct peripheral administration without supplementation of electrolytes and/or dextrose.
None Documented
None Documented
Amino acids have variable half-lives (minutes to hours); dextrose has a plasma half-life of ~2 hours under euglycemic conditions. Clinically, continuous infusion maintains steady state.
The terminal elimination half-life of amino acids from the infusion mixture is not uniformly defined; however, individual amino acids have half-lives ranging from 10 to 30 minutes. For the mixture, the effective half-life is clinically considered to be approximately 1-2 hours, reflecting rapid metabolic clearance. In renal impairment, the half-life may be prolonged due to reduced urea clearance.
Renal excretion of amino acids as urea and ammonia; dextrose is metabolized to CO2 and water. Approximately 90% of infused amino nitrogen is recovered in urine as urea within 24 hours. Dextrose is completely metabolized.
Aminosyn II 3.5% M is a crystalline amino acid solution. Amino acids are primarily eliminated by metabolic utilization for protein synthesis and energy production. Excess amino acids undergo deamination, with nitrogen excreted as urea in urine via renal route. Fecal and biliary excretion are negligible. Approximately 80-90% of infused nitrogen is recovered as urea in urine in patients with normal renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution